Lu-177 FAP-2286 for unknown primary cancer
Part of Cancer clinical trials.
This trial tests a radioactive drug called Lu-177 FAP-2286 for people with cancer that started in an unknown place (CUP). It may help shrink tumors by targeting a protein found on many cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cancer of unknown primary (CUP) that got worse after first chemotherapy.
- A special PET scan shows your tumors have high levels of a target protein (FAP).
- You are 18 or older and able to do daily activities with little help.
- Your blood counts, kidney, and liver function are good enough for treatment.
- You have not had more than one type of cancer treatment before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of PET-CT scan using a tracer called FAPI to find the original source of cancer when standard tests have not been able to. It may help identify the primary tumor in people with cancer that has spread from an unknown location.
This trial is for people with cancer of unknown primary (CUP), meaning cancer that started in an unknown place in the body. It aims to use advanced genomic testing (looking at your tumor's DNA) on your stored tumor sample and blood to find clues about where the cancer began and possible treatment options.
This trial tests how safe and effective a targeted radiation medicine (177Lu-FAP-2286) is for people with advanced solid cancers that have limited treatment options. It may help by delivering radiation directly to cancer-related targets and shrinking tumors.
This trial tests a new radioactive treatment (177Lu-FAP-2286) for people with advanced bladder cancer that has stopped responding to other therapies. It aims to see if this treatment can shrink tumors and how safe it is.
This trial tests a new radioactive drug, [177Lu]Lu-XT117, that seeks out and delivers radiation to solid tumors that have a specific marker called FAP. It's for people whose cancer has not responded to other treatments or who have no other options.
This trial tests a new radioactive treatment (177Lu-OncoFAP-23) alone or combined with an immunotherapy (L19-IL2) for people with advanced solid tumors that have a specific protein called FAP. It's for patients whose cancer has grown despite standard therapies.
Hear when a new Cancer of Unknown Primary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.